ProDa BioTech L.L.C.

Marietta, GA · Biotech · Private

ProAgio, a novel therapeutic protein designed to target integrin αvβ3 and induce apoptosis of cancer-associated pancreatic stellate cells and angiogenic endothelial cells

Grants
$6.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a protein drug for pancreatic cancer treatment$167,021
Federal grantDepartment of Health and Human Services · Phase II · Development of a protein drug for pancreatic cancer treatment$1,999,560
Federal grantDepartment of Health and Human Services · Phase II · Development of a protein drug for pancreatic cancer treatment$2,478,350
Federal grantDepartment of Health and Human Services · Phase II · A treatment drug for triple negative breast cancer$1,999,124
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2248NAPROGENIX, INC.——
2249BRIDGENE BIOSCIENCES, INC.——
2250OpalGenix, Inc.——
2251ProDa BioTech L.L.C.——
2252AUMENTA BIOSCIENCES, INC.——
2253General Reasoning, Inc.—$11M
2254ADDUCTNE LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Methods For Treating Fibrosis Using PKM2 Activatorsapplication
  • Methods For Treating Fibrosis Using PKM2 Activatorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.